Related Experiment Video

Updated: Aug 10, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Advances in developing novel therapeutic strategies for Alzheimer's disease

Jiqing Cao1,2,3, Jianwei Hou1,2, Jing Ping3

  • 1James J Peters VA Medical Center, Research & Development, Bronx, NY, 10468, USA.

Molecular Neurodegeneration
|December 14, 2018
PubMed

Insights

Alzheimer's Disease (AD) therapies face challenges due to complex causes. New drug development focuses on multiple targets and early prevention for slowing AD progression.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Alzheimer's Disease (AD) is a leading neurodegenerative disorder affecting older adults.
  • Current AD drug treatments have shown limited efficacy, highlighting a critical need for novel therapies.
  • The multifactorial nature of AD pathogenesis, involving amyloid plaques, neuroinflammation, and protein aggregation, complicates drug development.

Purpose of the Study:

  • To review current strategies and emerging trends in Alzheimer's Disease drug development.
  • To discuss the shift from single-target (amyloid-centric) approaches to multi-target therapies.
  • To explore the move towards preventive strategies and early-stage intervention for AD.

Main Methods:

  • Summary of pre-clinical and clinical trial data for AD therapeutics.
  • Analysis of mechanism-based versus non-mechanism-based treatment approaches.
  • Review of lifestyle modifications and risk factor management in AD prevention.

Main Results:

  • AD drug development is evolving beyond amyloid-focused strategies.
  • Multi-target drug design and early intervention are key emerging trends.
  • Symptomatic treatments, lifestyle changes, and risk factor management are crucial components of AD care.

Conclusions:

  • Effective Alzheimer's Disease treatment requires addressing its multifactorial nature.
  • Future AD therapies will likely involve combination strategies targeting various pathways.
  • Preventive measures and early intervention are essential for managing Alzheimer's Disease progression.
Keywords:
Alzheimer’s diseaseDrug developmentNovel therapiesPre-clinical and clinical trials

More Related Videos

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...